We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+17.78%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$261M
AUM Growth
-$12M
(-4.4%)
Cap. Flow
-$41.8M
Cap. Flow
% of AUM
-16.04%
Top 10 Holdings %
Top 10 Hldgs %
69%
Holding
42
New
10
Increased
3
Reduced
4
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$10.6M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$5.19M |
| 3 |
AtriCure
ATRC
|
+$3.24M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$3.22M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
+$2.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Melco Resorts & Entertainment
MLCO
|
+$14.3M |
| 2 |
Biogen
BIIB
|
+$8.81M |
| 3 |
Alcon
ALC
|
+$7.8M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
+$7.41M |
| 5 |
Charter Communications
CHTR
|
+$7.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.11% |
| 2 | Technology | 24.55% |
| 3 | Consumer Discretionary | 17.42% |
| 4 | Communication Services | 8.67% |
| 5 | Financials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cytokinetics
CYTK
$10.5B
| $1.88M | 0.72% |
+22,510
| New | +$815K |
|
27
Microsoft
MSFT
$3.43T
| $1.23M | 0.47% |
+3,275
| New | +$1.17M |
|
28
Toast
TOST
$18.8B
| $962K | 0.37% |
52,692
| – | – |
|
29
NextDecade
NEXT
$1.76B
| $324K | 0.12% |
+67,837
| New | +$316K |
|
30
Surrozen Inc Warrant
SRZNW
$69.7K
| $9.05K | ﹤0.01% |
466,666
| – | – |
|
|
AKRO
31
DELISTED
Akero Therapeutics
AKRO
| – | – |
-101,500
| Closed | -$5.13M |
|
|
32
Alcon
ALC
$33.5B
| – | – |
-101,227
| Closed | -$7.8M |
|
|
33
Biogen
BIIB
$30.3B
| – | – |
-34,261
| Closed | -$8.81M |
|
34
Bausch + Lomb
BLCO
$5.98B
| – | – |
-245,431
| Closed | -$4.16M |
|
35
Charles River Laboratories
CRL
$11.2B
| – | – |
-17,600
| Closed | -$3.45M |
|
36
DexCom
DXCM
$32.3B
| – | – |
-38,800
| Closed | -$3.62M |
|
37
Knife River
KNF
$4.18B
| – | – |
-68,199
| Closed | -$3.33M |
|
38
Insulet
PODD
$11.5B
| – | – |
-11,800
| Closed | -$1.88M |
|
39
Sotera Health
SHC
$5.09B
| – | – |
-260,400
| Closed | -$3.9M |
|
|
40
Surrozen
SRZN
$256M
| – | – |
-4,113
| Closed | -$30.2K |
|
41
Tenet Healthcare
THC
$20.4B
| – | – |
-58,500
| Closed | -$3.85M |
|
|
IMGN
42
DELISTED
Immunogen Inc
IMGN
| – | – |
-467,220
| Closed | -$7.41M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q4 2023 Portfolio in Review
As of Q4 2023, Bridger Management held 42 positions worth $261M, down 4.4% from $273M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Bridger Management withdrew a net $41.8M in Q4 2023, closing 12 positions and reducing 4 holdings. Its most notable exit was Biogen, an estimated $8.81M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 36% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Bridger Management opened a new position in Pfizer worth $10.1M.
- Bridger Management's largest Q4 2023 buy was Pfizer: 350,500 shares worth $10.1M.
- Bridger Management added most to uniQure in Q4 2023, an estimated $2.32M increase.
- Bridger Management's biggest Q4 2023 reduction was Melco Resorts & Entertainment, cutting an estimated $14.3M.
- Bridger Management fully exited Biogen in Q4 2023, selling an estimated $8.81M.
- Bridger Management's ten largest holdings make up 69% of its $261M portfolio in Q4 2023.
- Bridger Management opened 10 new positions and closed 12 in Q4 2023.
- Bridger Management's portfolio value fell 4.4% quarter-over-quarter to $261M.
Based on Bridger Management's 13F filing for Q4 2023, filed 14 Feb 2024.